Clare Market Investments LLC Makes New $2.53 Million Investment in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Clare Market Investments LLC bought a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 4,844 shares of the medical equipment provider’s stock, valued at approximately $2,528,000. Intuitive Surgical accounts for 0.6% of Clare Market Investments LLC’s holdings, making the stock its 26th biggest holding.

Several other hedge funds have also made changes to their positions in the company. Berbice Capital Management LLC bought a new position in Intuitive Surgical in the fourth quarter worth about $26,000. BankPlus Trust Department acquired a new stake in shares of Intuitive Surgical in the 4th quarter worth $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter worth $31,000. MidAtlantic Capital Management Inc. purchased a new position in Intuitive Surgical in the 3rd quarter worth $33,000. Finally, Decker Retirement Planning Inc. purchased a new position in Intuitive Surgical in the 4th quarter worth $36,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ISRG. Jefferies Financial Group raised their target price on Intuitive Surgical from $475.00 to $575.00 in a research note on Monday, January 27th. Evercore ISI raised their target price on Intuitive Surgical from $490.00 to $530.00 in a research note on Monday, January 27th. Morgan Stanley upgraded Intuitive Surgical from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $522.00 to $650.00 in a research note on Monday, December 2nd. Barclays raised their target price on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Finally, Wells Fargo & Company lifted their price objective on Intuitive Surgical from $630.00 to $687.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average target price of $613.10.

Insider Buying and Selling

In related news, Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the sale, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. The trade was a 27.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Jamie Samath sold 270 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $540.15, for a total value of $145,840.50. Following the transaction, the chief financial officer now owns 8,757 shares in the company, valued at approximately $4,730,093.55. This represents a 2.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,579 shares of company stock worth $7,756,844. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Trading Down 3.8 %

ISRG stock opened at $518.26 on Monday. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00. The stock has a market cap of $184.59 billion, a price-to-earnings ratio of 80.85, a PEG ratio of 5.85 and a beta of 1.43. The business’s 50-day moving average is $571.36 and its 200 day moving average is $531.85.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.